State Of Wyoming Neurocrine Biosciences Inc Transaction History

State Of Wyoming

$676 Million
Q3 2024

A detailed history of State Of Wyoming transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, State Of Wyoming holds 1,503 shares of NBIX stock, worth $205,204. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,503

Previous 1,376 9.23%

Holding current value

$205,204

Previous $189,000 8.47%

% of portfolio

0.03%

Previous 0.03%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $14,551 - $19,450	127 Added 9.23%	1,503 $173,000
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $180,063 - $197,029	1,376 New	1,376 $189,000
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $17,501 - $21,905	165 Added 28.25%	749 $98,000
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $54,907 - $68,386	584 New	584 $65,000
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $10,352 - $13,532	110 Added 6.26%	1,866 $188,000
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $155,491 - $185,126	1,457 Added 487.29%	1,756 $209,000
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $22,179 - $25,982	241 Added 415.52%	299 $32,000
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $1,061 - $1,400	14 Added 31.82%	58 $6,000
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $579 - $758	8 Added 22.22%	44 $4,000
Q4 2021 Feb 11, 2022	SELL	$79.65 - $106.22 $238 - $318	-3 Reduced 7.69%	36 $3,000
Q3 2021 Feb 11, 2022	SELL	$86.18 - $99.03 $1,551 - $1,782	-18 Reduced 31.58%	39 $4,000
Q2 2021 Feb 11, 2022	BUY	$89.43 - $102.27 $2,682 - $3,068	30 Added 111.11%	57 $6,000
Q1 2021 Feb 08, 2022	BUY	$87.57 - $119.4 $2,364 - $3,223	27 New	27 $3,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account